Patent ID: 8758752

Claim:
A method of treating cancer comprising: a) obtaining an isolated humanized anti-TROP-2 antibody or fragment thereof that competes for binding to the same epitope of TROP-2 with that of a murine antibody comprising light chain variable region CDR1 KASQDVSIAVA (SEQ ID NO:28), CDR2 SASYRYT (SEQ ID NO:29) and CDR3 QQHYITPLT (SEQ ID NO:30) and heavy chain variable region CDR1 NYGMN (SEQ ID NO:31), CDR2 WINTYTGEPTYTDDFKG (SEQ ID NO:32) and CDR3 GGFGSSYWYFDV (SEQ ID NO:33); and b) administering the antibody or fragment thereof to a subject with a TROP-2 positive cancer; wherein the humanized anti-TROP-2 antibody or fragment thereof is conjugated to at least one therapeutic agent selected from the group consisting of a drug, an immunomodulator, a hormone, an enzyme, a growth factor, a radionuclide, an antisense oligonucleotide, an anti-angiogenic agent and a pro-apoptotic agent.